OneDigital Investment Advisors LLC Acquires 2,065 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

OneDigital Investment Advisors LLC increased its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 52.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,989 shares of the company's stock after acquiring an additional 2,065 shares during the quarter. OneDigital Investment Advisors LLC's holdings in TransMedics Group were worth $403,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. NBC Securities Inc. bought a new stake in TransMedics Group in the 1st quarter valued at $25,000. Atlas Capital Advisors Inc. acquired a new position in shares of TransMedics Group during the fourth quarter valued at about $31,000. AlphaQuest LLC bought a new stake in shares of TransMedics Group in the fourth quarter valued at about $52,000. Rakuten Securities Inc. grew its position in TransMedics Group by 68.3% during the fourth quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock worth $84,000 after buying an additional 550 shares in the last quarter. Finally, Sava Infond d.o.o. acquired a new stake in TransMedics Group during the fourth quarter worth about $94,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of research reports. Oppenheimer raised their price objective on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and an average target price of $127.33.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 6,000 shares of the stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director directly owned 732 shares of the company's stock, valued at $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,418 shares of company stock valued at $1,512,613. Insiders own 7.00% of the company's stock.

TransMedics Group Price Performance

TransMedics Group stock traded down $12.32 during trading hours on Friday, hitting $112.46. 2,553,123 shares of the stock were exchanged, compared to its average volume of 1,375,641. The stock has a market capitalization of $3.80 billion, a P/E ratio of 82.69 and a beta of 2.06. The business's 50-day moving average is $125.04 and its two-hundred day moving average is $90.13. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. TransMedics Group's revenue for the quarter was up 48.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.35 EPS. Equities research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.